Example searches

TXMD TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Company profile

Ticker
TXMD
Exchange
NASDAQ
Website
www.therapeuticsmd.com
CEO
Robert G. Finizio
Employees
Incorporated in
Nevada
Location
Florida
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Generic
Industry (SEC)
Pharmaceutical Preparations
Pfizer • Merck & Co. • Allergan • Johnson & Johnson • Abbott Laboratories • Teva Pharmaceutical Industries • Bristol Myers Squibb • ELI LILLY & Co • Warner Chilcott • AbbVie ...
Former names
AMHN, Inc., Croff Enterprises Inc, Croff Oil Co
SEC CIK
0000025743
Corporate docs
IRS number
870233535

TXMD stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 20
14 Jul 20
31 Dec 20

News

Company financial data Financial data

Chart TXMD financial data
Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 12.25M 15.9M 23.72M 6.08M
Net income -56.85M -49.44M -31.97M -55.24M
Diluted EPS -0.21 -0.19 -0.13 -0.23
Net profit margin -464% -311% -135% -909%
Operating income -50.92M -44.39M -27.07M -41.64M
Net change in cash 9.27M 5.5M -27.52M 59.96M
Cash on hand 170.1M 160.83M 155.33M 182.85M
Cost of revenue 2.72M 2.88M 1.44M 1.25M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 49.65M 16.1M 16.78M 19.36M
Net income -176.14M -132.62M -76.93M -89.88M
Diluted EPS -0.72 -0.59 -0.37 -0.46
Net profit margin -355% -824% -458% -464%
Operating income -151.21M -130.22M -77.63M -90.25M
Net change in cash -783.36K 34.48M -4.4M 66.83M
Cash on hand 160.83M 161.61M 127.14M 131.53M
Cost of revenue 6.33M 2.74M 2.64M 4.19M

Financial data from company earnings reports

Recent insider trades

TXMD insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 James DArecca RSU Common Stock Grant Aquire A No 0 651,500 0 651,500
18 Jun 20 James DArecca Performance Stock Units Common Stock Grant Aquire A No 0 151,500 0 151,500
18 Jun 20 Musing Jules A. RSU Common Stock Grant Aquire A No 0 96,864 0 96,864
18 Jun 20 Ling Karen RSU Common Stock Grant Aquire A No 0 96,864 0 96,864
18 Jun 20 Collins Cooper C. RSU Common Stock Grant Aquire A No 0 96,864 0 96,864
18 Jun 20 Carroll J Martin RSU Common Stock Grant Aquire A No 0 96,864 0 96,864
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

TXMD institutional ownership history Ownership history
67.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 141 171 -17.5%
Opened positions 9 32 -71.9%
Closed positions 39 14 +178.6%
Increased positions 38 56 -32.1%
Reduced positions 53 40 +32.5%
13F shares
 Current Prev Q Change
Total value 189.01M 466.78M -59.5%
Total shares 182.06M 192.45M -5.4%
Total puts 524.8K 806K -34.9%
Total calls 439.9K 914K -51.9%
Total put/call ratio 1.2 0.9 +35.3%
Largest owners
 Shares Value Change
N Price T Rowe Associates 19.36M $20.52M +0.6%
JPM JPMorgan Chase & Co. 19.28M $20.44M -2.2%
BLK BlackRock 17.94M $19.01M -1.8%
Vanguard 16.99M $18.01M +2.4%
FMR 16.67M $17.67M -5.7%
BK Bank Of New York Mellon 12.68M $13.44M -3.3%
Rubric Capital Management 9.61M $10.19M -12.7%
BEN Franklin Resources 6.59M $6.99M -30.5%
C WorldWide Group Holding A/S 6.19M $6.56M +94.0%
STT State Street 5.47M $5.8M -1.1%
Largest transactions
 Shares Bought/sold Change
Frontier Capital Management 0 -6.41M EXIT
GMT Capital 5.14M +5.14M NEW
Sanders Morris Harris 3.75M +3.38M +911.5%
C WorldWide Group Holding A/S 6.19M +3M +94.0%
BEN Franklin Resources 6.59M -2.89M -30.5%
Deerfield Management 0 -2.25M EXIT
IVZ Invesco 43.98K -1.88M -97.7%
Citadel Advisors 1.8M +1.51M +523.7%
Rubric Capital Management 9.61M -1.4M -12.7%
AMP Ameriprise Financial 4.84M +1.39M +40.3%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Mylan • Pfizer • AMAG Pharmaceuticals • Allergan • Agile Therapeutics • VMS • Allergan • Mylan • Amneal Pharmaceuticals • Amneal Pharmaceuticals
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absorption, ACA, acquire, acquired, add, addressable, Addressing, adequate, affirmative, amenorrhea, anniversary, Bank, banking, behavior, belief, billion, blood, BofA, bothersome, breadth, cancel, cancelling, case, cessation, chosen, collateral, comfortable, comprehensive, concentration, condensed, conserve, contemporaneously, country, critical, cut, cutting, damage, Defense, deferral, demand, demonstrated, demonstrating, Department, detail, detailed, detailing, difficult, disbursed, displaced, disruption, dissatisfied, distancing, doctor, easy, economy, employment, empowering, endpoint, energizing, enhanced, entertainment, environment, evolution, evolved, evolving, failure, family, fashion, fertility, foresee, forgiven, freeze, frequency, function, functional, functioning, gain, group, growth, hand, headcount, high, hiring, home, identification, IMMVEXXY, incipient, inhibit, interruption, IP, IUD, Joyesta, largely, larger, largest, lever, likelihood, local, lost, lunch, mail, mailing, meaningful, mechanism, media, meet, meeting, menstruation, mind, mission, mitigate, motived, NA, notice, NuvaRing, offline, online, optimistic, outbreak, PA, pandemic, Paragraph, pause, paused, Paycheck, payroll, peanut, permanent, Pharma, pharmacopogical, postmenopausal, power, PPP, practitioner, preclude, predict, predicted, predisposed, premier, preserve, pressure, procedure, profitability, promissory, prorated, Puerto, pull, quantitative, quickly, ramp, ramping, rapidly, ratio, reassessed, recession, refill, regimen, remotely, reputation, rest, restarted, resume, Rico, ring, SA, SBA, sector, shortage, sooner, span, speak, spent, spread, stay, steady, step, streamline, suspend, suspended, suspending, sustain, sustained, telemedicine, traditional, training, twelve, unbranded, underrepresented, unemployment, uninterrupted, unique, unknown, usage, Veteran, vi, virtual, visit, week, world, worldwide, worse
Removed: amending, antidilutive, assume, block, campaign, capacity, championing, childbirth, circumstance, classification, closing, Comparative, comparing, concurrent, constraint, core, criteria, decrease, dependent, designation, designing, distinct, dosage, evaluating, executed, executing, expansion, expedient, facing, familiarizing, FD, filled, finance, fulfill, fuller, goal, greatly, highlighting, implementation, increasing, informed, instituted, introducing, journal, medical, multichannel, NES, nursing, OCs, offering, origination, package, partner, periodic, pharmacovigilance, piloted, practical, precedent, print, reached, recalculated, recognizing, recoverability, recruiting, repaid, resulted, revised, sample, SAR, simplify, specifically, subjective, subscription, suggest, Supplemental, SYMBODA, timing, underwritten, unmet, utilized, vendor, waiver
From filing 10-Q 2020 Q1

Financial reports

View all
10-Q
2020 Q1
Quarterly report
6 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
30 Jul 18
10-Q
2018 Q1
Quarterly report
7 May 18

Current reports

View all
8-K
Regulation FD Disclosure
23 Jun 20
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Departure of Directors or Certain Officers
1 Jun 20
8-K
Termination of a Material Definitive Agreement
15 May 20
8-K
Regulation FD Disclosure
13 May 20
8-K
TherapeuticsMD Announces First Quarter 2020 Financial Results
6 May 20
8-K
Entry into a Material Definitive Agreement
1 May 20
8-K
Departure of Directors or Certain Officers
22 Apr 20
8-K
TherapeuticsMD Provides COVID-19-Related Business Update
26 Mar 20
8-K
Departure of Directors or Certain Officers
24 Mar 20

Registration and prospectus

View all
POS AM
Prospectus update (post-effective amendment)
24 Feb 20
424B2
Prospectus for primary offering
25 Oct 19
FWP
Free writing prospectus
24 Oct 19
FWP
Free writing prospectus
23 Oct 19
424B5
Prospectus supplement for primary offering
23 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19
424B2
Prospectus for primary offering
2 Aug 18
424B2
Prospectus for primary offering
2 Aug 18
424B5
Prospectus supplement for primary offering
31 Jul 18

Proxies

View all
DEFA14A
Additional proxy soliciting materials
4 May 20
DEF 14A
Definitive proxy
4 May 20
PRER14A
Preliminary revised proxy
22 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
25 Apr 17

Other

View all
EFFECT
Notice of effectiveness
6 May 20
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
21 Aug 18
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
UPLOAD
Letter from SEC
25 Jan 17
CORRESP
Correspondence with SEC
29 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
EFFECT
Notice of effectiveness
17 Nov 15

Ownership

View all
4
TherapeuticsMD / PAUL BISARO ownership change
19 Jun 20
4
TherapeuticsMD / Tommy G Thompson ownership change
19 Jun 20
4
TherapeuticsMD / Angus C. Russell ownership change
19 Jun 20
4
TherapeuticsMD / Gail K Naughton ownership change
19 Jun 20
4
TherapeuticsMD / JULES A. MUSING ownership change
19 Jun 20
4
TherapeuticsMD / Karen Ling ownership change
19 Jun 20
4
TherapeuticsMD / Cooper C. Collins ownership change
19 Jun 20
4
TherapeuticsMD / J MARTIN CARROLL ownership change
19 Jun 20
4
TherapeuticsMD / James DArecca ownership change
19 Jun 20
4
TherapeuticsMD / Cooper C. Collins ownership change
10 Jun 20

Patents

View all
APP
Utility
CorrectedVaginal Inserted Estradiol Pharmaceutical Compositions and Methods
2 Jul 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
GRANT
Utility
Natural combination hormone replacement formulations and therapies
9 Jun 20
Estrogen and progesterone replacement therapies are provided herein.
APP
Utility
Soluble Estradiol Capsule for Vaginal Insertion
4 Jun 20
According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided.
GRANT
Reissue
Mold for a medical dosage form
2 Jun 20
Inventors: Frederick D. Sancilio, Thorsteinn Thorsteinsson, Julia M. Amadio
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
2 Jun 20
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).